Umbralisib, a PI3Kδ/CK1ε dual inhibitor demonstrates marked clinical activity in patients with relapsed or refractory indolent non-Hodgkin lymphoma: Results from the Phase 2 global UNITY-NHL trial

Drug Category : Array
Conference Category : Array
Lead Author : Zinzani P, et al.
Published Date : 07/12/2020
Download Link : https://www.tgtherapeutics.com/wp-content/uploads/2020/12/ASH2020ZinzaniPUNHL.pdf
Download Text : Download
Popup Confirmation? :
site-sidebar-layout : default
ast-site-content-layout : default
site-content-style : default
site-sidebar-style : default
theme-transparent-header-meta : default
stick-header-meta : default
astra-migrate-meta-layouts : set
Scroll to Top